QureBio’s Q-1802 Clinical Application Accepted by NMPA

News

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2020-12-30

Source: Viva Biotech

[Abstract]:The first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.

SHANGHAI, CHINA---- Recently, QureBio (Shanghai) Co., Ltd. (hereinafter referred to as QureBio), which is invested and incubated by Viva BioInnovator and focused on the R&D of innovative macromolecular biopharmaceuticals, announced that the Center for Drug Evaluation, NMPA, has accepted the clinical trial application of its recombinant anti-Claudin 18.2 and PD-L1 humanized bispecific antibody for injection (code: Q-1802) according to "Category 1 of Therapeutic Biological Novel Products".

Official data shows that Q-1802 is the first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.

Previous Page：The U.S. Food and Drug Administration granted IND approval for Q-1802 Next Page：Xlement Attended 3rd China International Import Exhibition

Back

Media contact: vivapr@vivabiotech.com